Treatment dynamics of newly marketed drugs and implications for comparative effectiveness research

Value in Health

Volumn 16, Issue 6, 2013, Pages 1054-1062

  Gagne, Joshua J ^a   Bykov, Katsiaryna ^a   Willke, Richard J ^b   Kahler, Kristijan H ^c   Subedi, Prasun ^b   Schneeweiss, Sebastian ^a  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

^b PFIZER INC   (United States)

^c NOVARTIS PHARMA AG   (Switzerland)

Author keywords

effectiveness new drugs prospective monitoring validity

Indexed keywords

ALENDRONIC ACID; EZETIMIBE PLUS SIMVASTATIN; NONSTEROID ANTIINFLAMMATORY AGENT; RALOXIFENE; RISEDRONIC ACID; ROFECOXIB;

ARTICLE; COHORT ANALYSIS; COMPARATIVE EFFECTIVENESS; DRUG MARKETING; DYNAMICS; EXPECTATION; FRACTURE; GASTROINTESTINAL HEMORRHAGE; HEART INFARCTION; HUMAN; MONITORING; PRIORITY JOURNAL; RISK ASSESSMENT; SOCIAL MARKETING;

EFFECTIVENESS; NEW DRUGS; PROSPECTIVE MONITORING; VALIDITY;

COMPARATIVE EFFECTIVENESS RESEARCH; DRUG MONITORING; DRUG SUBSTITUTION; DRUG THERAPY, COMBINATION; HUMANS; INSURANCE CLAIM REVIEW; NEW JERSEY; PENNSYLVANIA; PRESCRIPTION DRUGS;

EID: 84884290134     PISSN: 10983015     EISSN: 15244733     Source Type: Journal    
DOI: 10.1016/j.jval.2013.05.008     Document Type: Article

References (34)

1. J. Avorn In defense of pharmacoepidemiology - embracing the yin and yang of drug research N Engl J Med 357 2007 2219 2221
2. N.H. Goldberg, S. Schneeweiss, M.K. Kowal, and J.J. Gagne Availability of comparative efficacy data at the time of drug approval in the United States JAMA 305 2011 1786 1789
3. J.J. Gagne, and N.K. Choudhry How many "me-too" drugs is too many? JAMA 305 2011 711 712
4. S. Schneeweiss, J.J. Gagne, and A.R. Patrick Comparative efficacy and safety of new oral anticoagulants in patients with atrial fibrillation Circ Cardiovasc Qual Outcomes 5 2012 480 486
5. S. Schneeweiss, J.J. Gagne, and R.J. Glynn Assessing the comparative effectiveness of newly marketed medications: methodological challenges and implications for drug development Clin Pharmacol Ther 90 2011 777 790
6. C.D. Blosser, A. Huverserian, and R.D. Bloom Age, exclusion criteria, and generalizability of randomized trials enrolling kidney transplant recipients Transplantation 91 2011 858 863
7. J.H. Gurwitz, N.F. Col, and J. Avorn The exclusion of the elderly and women from clinical trials in acute myocardial infarction JAMA 268 1992 1417 1422
8. J. Travers, S. Marsh, and M. Williams External validity of randomised controlled trials in asthma: to whom do the results of the trials apply? Thorax 62 2007 219 223
9. S.M. Greene, R.J. Reid, and E.B. Larson Implementing the learning health system: from concept to action Ann Intern Med 157 2012 207 210
10. S. Schneeweiss, and J. Avorn A review of uses of health care utilization databases for epidemiologic research on therapeutics J Clin Epidemiol 58 2005 323 337
11. S. Schneeweiss Developments in post-marketing comparative effectiveness research Clin Pharmacol Ther 82 2007 143 156
12. P.J. Neumann, J.D. Chambers, F. Simon, and L.M. Meckley Risk-sharing arrangements that link payment for drugs to health outcomes are proving hard to implement Health Aff (Millwood) 30 2011 2329 2337
13. R. Platt, R.M. Carnahan, J.S. Brown The U.S. Food and Drug Administration's Mini-Sentinel program: status and direction Pharmacoepidemiol Drug Saf 21 Suppl. 1 2012 1 8
14. J.J. Gagne, R.J. Glynn, and J.A. Rassen Active safety monitoring of newly marketed medications in a distributed data network: application of a semi-automated monitoring system Clin Pharmacol Ther 92 2012 80 86
15. J.J. Gagne, J.A. Rassen, and A.M. Walker Active safety monitoring of new medical products using electronic healthcare data: selecting alerting rules Epidemiology 23 2012 238 246
16. Y. Kiyota, S. Schneeweiss, and R.J. Glynn Accuracy of Medicare claims-based diagnosis of acute myocardial infarction: estimating positive predictive value on the basis of review of hospital records Am Heart J 148 2004 99 104
17. P.M. Wahl, K. Rodgers, and S. Schneeweiss Validation of claims-based diagnostic and procedure codes for cardiovascular and gastrointestinal serious adverse events in a commercially-insured population Pharmacoepidemiol Drug Saf 19 2010 596 603
18. D.L. Tirschwell, and W.T. Longstreth Jr Validating administrative data in stroke research Stroke 33 2002 2465 2470
19. J.J. Gagne, A.R. Patrick, H. Mogun, and D.H. Solomon Antidepressants and fracture risk in older adults: a comparative safety analysis Clin Pharmacol Ther 89 2011 880 887
20. W.A. Ray, M.R. Griffin, R.L. Fought, and M.L. Adams Identification of fractures from computerized Medicare files J Clin Epidemiol 45 1992 703 714
21. W.A. Ray Evaluating medication effects outside of clinical trials: new-user designs Am J Epidemiol 158 2003 915 920
22. J.J. Gagne, R.J. Glynn, and J. Avorn A combined comorbidity score predicted mortality in elderly patients better than existing scores J Clin Epidemiol 64 2011 749 759
23. P.G. Arbogast, and W.A. Ray Use of disease risk scores in pharmacoepidemiologic studies Stat Methods Med Res 18 2009 67 80
24. S.M. Cadarette, J.J. Gagne, and D.H. Solomon Confounder summary scores when comparing the effects of multiple drug exposures Pharmacoepidemiol Drug Saf 19 2010 2 9
25. B.B. Hansen The prognostic analogue of the propensity score Biometrika 95 2008 8
26. R.J. Glynn, J.J. Gagne, and S. Schneeweiss Role of disease risk scores in comparative effectiveness research with emerging therapies Pharmacoepidemiol Drug Saf 21 Suppl. 2 2012 138 147
27. J.J. Gagne, A.M. Walker, and R.J. Glynn An event-based approach for comparing the performance of methods for prospective medical product monitoring Pharmacoepidemiol Drug Saf 21 2012 631 639
28. P.R. Rosenbaum, and D.B. Rubin The central role of the propensity score in observational studies for causal effects Biometrika 70 1983 41 55
29. S. Schneeweiss, J.A. Rassen, and R.J. Glynn High-dimensional propensity score adjustment in studies of treatment effects using health care claims data Epidemiology 20 2009 512 522
30. J.A. Rassen, and S. Schneeweiss Using high-dimensional propensity scores to automate confounding control in a distributed medical product safety surveillance system Pharmacoepidemiol Drug Saf 21 Suppl. 1 2012 41 49
31. C. Bombardier, L. Laine, and A. Reicin Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis VIGOR Study Group. N Engl J Med 343 2000 1520 1528 2 p following 8
32. J.J. Gagne, B. Fireman, and P.B. Ryan Design considerations in an active medical product safety monitoring system Pharmacoepidemiol Drug Saf 21 Suppl. 1 2012 32 40
33. M.A. Hernan, A. Alonso, and R. Logan Observational studies analyzed like randomized experiments: an application to postmenopausal hormone therapy and coronary heart disease Epidemiology 19 2008 766 779
34. E.S. Johnson, B.A. Bartman, and B.A. Briesacher The incident user design in comparative effectiveness research Pharmacoepidemiol Drug Saf 22 2013 1 6